At variance with normal cells, which derive their lipids from dietary intake or from lipid metabolism in the liver, cancer cells activate de novo lipogenesis, whose limiting enzyme is the fatty acid synthase (FASN, Fig. 1). The gene discussed is FASN; the disease is cancer.